<DOC>
	<DOCNO>NCT00001998</DOCNO>
	<brief_summary>To define pharmacokinetic characteristic Nystatin LF IV ( intravenous ) human subject AIDS-related complex ( ARC ) administration single IV dose 4 dose level .</brief_summary>
	<brief_title>Pharmacokinetics Nystatin LF I.V . Patients With Acquired Immune Deficiency Syndrome-Related Complex ( ARC )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Positive HIV antibody test . Diagnosis AIDSrelated complex ( ARC ) . CD4+ cell count 100 300 cells/mm3 . Estimated life expectancy least 6 month . Normal neurological status . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection require ongoing therapy except patient treat topically oral thrush . Patients follow exclude : Active opportunistic infection . Known hypersensitivity polyene antibiotic . Unwillingness sign inform consent compliance protocol requirement . Prior Medication : Excluded within 72 hour study entry : Biologic response modifier agent . Corticosteroids . Cytotoxic chemotherapeutic agent . Potential nephrotoxin . Potential neutropenic agent . Rifampin rifampin derivative . Systemic antiinfectives . Phenytoin barbiturate ( inducer microsomal enzyme ) . All systemic medication . Prior Treatment : Excluded within 72 hour prior study entry : Radiation therapy . Active alcohol drug abuse unless drug and/or alcohol two week prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1992</verification_date>
	<keyword>Nystatin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>